Repare licenses lunresertib worldwide to Debiopharm for $10M upfront, up to $257M milestones

Repare Therapeutics Inc.

$10M upfront payment; eligible for up to $257M in clinical, regulatory, commercial milestones including $5M near-term.
Single-digit royalties on global net sales; Debiopharm responsible for all development costs and MYTHIC trial sponsorship.
Repare to focus on Phase 1 POLAR trial (RP-3467, data Q3 2025) and LIONS trial (RP-1664, data Q4 2025).
Agreement builds on Jan 2024 collaboration exploring lunresertib + Debio 0123 (WEE1 inhibitor).

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.